🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

26 recruiting trials

for Glycogen Storage Disease Type II

Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology NCT07136844NA1 site📍 Liège Centre Hospitalier Universitaire de Liege · Tests: Syde, Dynamometric measurements of muscle strength, The 6-minute walk test (6MWT), The 10-meter test (10MWT), The 4 sta… Natural History of Pompe Disease NCT03564561n/a1 site📍 Garches Assistance Publique - Hôpitaux de Paris A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD) NCT07282847Phase 1, Phase 29 sites📍 Phoenix📍 Irvine📍 Palo Alto AskBio Inc · Tests: AB-1009 (GAA Gene) PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) NCT04532047Phase 11 site📍 San Francisco University of California, San Francisco · Tests: Aldurazyme (laronidase) Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases NCT06833489NA1 site📍 Marseille Assistance Publique Hopitaux De Marseille · Tests: ARN extraction from muscle biopsies Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) NCT07123155Phase 228 sites📍 Irvine📍 Gainesville📍 Atlanta Shionogi · Tests: S-606001, Placebo A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease NCT07354724Phase 14 sites📍 Irvine📍 St Louis📍 Durham Denali Therapeutics Inc. · Tests: DNL952 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health Rare Glycogen Storage Diseases Natural History Study NCT06795152n/a1 site📍 Durham Duke University · Tests: No intervention A Long-term Study for the Outcome of Pompe Disease NCT02399748n/a1 site📍 Taipei National Taiwan University Hospital A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD NCT06557369NA1 site📍 Bergamo Oculox Technologies SA · Tests: reSEES Pompe Pregnancy Sub-Registry NCT00567073n/a35 sites📍 Phoenix📍 Jacksonville📍 Atlanta Genzyme, a Sanofi Company Pompe Disease RWE Long-term Monitoring Program NCT07834320n/a1 site📍 Taipei National Taiwan University Hospital Registry of Patients Diagnosed With Lysosomal Storage Diseases NCT05619900n/a1 site📍 San Francisco University of California, San Francisco · Tests: There is no intervention Pompe Disease Registry Protocol NCT00231400n/a272 sites📍 Birmingham📍 Phoenix📍 Phoenix Genzyme, a Sanofi Company Cognitive and Neurological Pathologies in Pompe Disease NCT04639336n/a1 site📍 Durham Duke University Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease NCT01665326n/a1 site📍 Durham Duke University · Tests: Observational Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug NCT06391736Phase 1, Phase 21 site📍 Beijing GeneCradle Inc · Tests: GC301 Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease NCT07478172NA1 site📍 Columbia University of Missouri-Columbia · Tests: Whole-body Electrical Muscle Stimulation Exercise Long-Term Development of Muscular Dystrophy Outcome Assessments NCT05989620n/a1 site📍 Richmond Virginia Commonwealth University China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD NCT06666413Phase 41 site📍 Shanghai Genzyme, a Sanofi Company · Tests: Avalglucosidase alfa Avalglucosidase Alfa Pregnancy Study NCT05734521n/a1 site📍 Bridgewater Sanofi · Tests: avalglucosidase alfa-NGPT (GZ402666) IV, avalglucosidase alfa-NGPT (GZ402666) A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 NCT04808505Phase 314 sites📍 Gainesville📍 Atlanta📍 Durham Amicus Therapeutics · Tests: Cipaglucosidase alfa, Miglustat Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals NCT06875245Phase 41 site📍 Prague Faculty Hospital Kralovske Vinohrady · Tests: Faricimab Injection A Global Prospective Observational Registry of Patients With Pompe Disease NCT06121011n/a41 sites📍 Little Rock📍 Irvine📍 Jacksonville Amicus Therapeutics · Tests: Cipaglucosidase alfa, Miglustat, Alglucosidase alfa or Avalglucosidase alfa, Untreated Phrenic Nerve and Diaphragm Electrophysiology in Pompe Disease NCT07664930n/a1 site📍 Pavia IRCCS National Neurological Institute "C. Mondino" Foundati…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy